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Metformin is a drug commonly prescribed to treat patients with type 2 diabetes. Here we show
that long-term treatment with metformin (0.1% w/w in diet) starting at middle age extends
healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Treatment with
metformin mimics some of the benefits of calorie restriction, such as improved physical
performance, increased insulin sensitivity, and reduced LDL and cholesterol levels without a
decrease in caloric intake. At a molecular level, metformin increases AMP-activated protein
kinase activity and increases antioxidant protection, resulting in reductions in both oxidative
damage accumulation and chronic inflammation. Our results indicate that these actions may
contribute to the beneficial effects of metformin on healthspan and lifespan. These findings are in
agreement with current epidemiological data and raise the possibility of metformin-based
interventions to promote healthy aging.
Metformin is a biguanide used since the 1960’s in the treatment of type 2 diabetes and
metabolic syndrome. It enhances insulin sensitivity, induces glycolysis and suppresses
gluconeogenesis in the liver1–3. Patients with metabolic syndrome exhibit many
manifestations of accelerated aging, such as cardiovascular disease, cancer and
inflammatory disorders, all of which reduce lifespan. The fact that metformin treatment has
been associated with reduced risk of cancer4 and cardiovascular disease raises the possibility
of a beneficial role of metformin for other age-related diseases5. Recently, we and others
have studied pharmacological interventions that can delay aging and the incidence of age-
related diseases6,7. Many of these interventions are based on the study of calorie restriction
(CR) mimetics8,9. CR mimetics involve interventions that reproduce physiological and anti-
aging effects found in CR animals. Several reports suggest that the actions of metformin
resemble the effects of CR to some extent; microarray analyses have shown that metformin
induces a gene expression profile that aligns with that of CR, although conflicting results
have been shown in lifespan extension9–15.
The mechanism of action of metformin involves, at least in part, activation of adenosine
monophosphate-activated protein kinase (AMPK), an enzyme involved in cellular and
whole-organism energy balance, as well as glucose and fat metabolism16,17. Separate
evidence suggests that metformin may also act via AMPK-independent mechanisms3,18,19.
The activation of AMPK is a well-known process triggered by an increase of the AMP/ATP
ratio20. Several studies provide evidence that metformin partially inhibits complex I of the
electron transport chain (ETC) with subsequent alteration of the mitochondrial performance,
but the molecular mechanisms underlying this process have not been characterized in
detail21–23. Thus, metformin may compromise ATP production in mitochondria leading to
an increase of the AMP/ATP ratio. As a consequence of energy depletion, glycolysis is
induced to maintain cellular metabolism. Even though mitochondrial poisons increase
oxidative cellular damage by mechanisms involving increased reactive oxygen species24,25,
there is no evidence that metformin induces the generation of reactive oxygen species and/or
accumulation of oxidative damage26,27. In fact, the transcription factor SKN-1/Nrf2 is
activated upon metformin treatment, resulting in increased expression of antioxidant genes
in cells and animal models10. Reduced accumulation of oxidative damage may contribute to
the inhibitory effects of metformin treatment in carcinogenesis models3,28,29.
The ability of metformin to extend lifespan in the nematode C. elegans and the conflicting
results in drosophila and mammals led us to study chronic metformin supplementation in
laboratory mice9,10,12. Cohorts of middle-aged male C57BL/6 and B6C3F1 mice were
provided with either a standard diet (SD) or SD supplemented with 0.1% (w/w) or 1% (w/w)
metformin for the remainder of their lives. Our data show a level of chronic metformin
exposure that leads to healthier and longer lives in mice, justifying further studies to
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determine if there is an exposure level that leads to improvement in healthspan and lifespan
in humans.
Results
Metformin increases healthspan and longevity of mice
We determined the long-term effects of two doses of metformin in male C57BL/6 mice. The
first dose consisted of 0.1% metformin (w/w) supplemented in diet, which yielded a
concentration of 0.45 ± 0.09 mM in serum and 0.49 ± 0.06 nmoles.mg−1 protein in the liver.
The second dose (1% w/w) yielded a concentration of 5.03 ± 0.87 mM in serum and 3.67 ±
0.32 nmoles.mg−1 protein in the liver (n = 6–8 per group; age = 84 weeks; diet = 30 weeks;
values presented as mean ± SEM). The survival curves of control and metformin-treated
male mice separated shortly after the onset of the treatment. Diet supplementation with 0.1%
metformin led to a 5.83% extension of mean lifespan (Fig. 1a), χ2 = 5.46 and p= 0.02 in
Gehan-Breslow survival test. In agreement with these data, a different strain of male mice
(B6C3F1) supplemented with the same dose of metformin (0.1% w/w) resulted in a 4.15%
extension of mean lifespan (Supplementary Fig. S1), χ2 = 3.43 and p= 0.064 in Gehan-
Breslow survival test, which although is not significant suggests that the effects of
metformin in longevity are not strain-specific. On the other hand, a higher concentration of
the drug (1% w/w) was toxic and significantly shortened mean lifespan of C57BL/6 mice by
14.4% (Fig. 1b), likely due to renal failure (Supplementary Fig. S1 and Supplementary
Table S1), χ2 = 51,70 and P< 0.001 in Gehan-Breslow survival test. High doses of
metformin have been associated with the development of lactic acidosis and the drug is
contraindicated in patients with kidney dysfunction30. Importantly, male mice treated with
0.1% metformin in both longevity studies did not show any major difference in pathologies
at 115 weeks of age nor obvious causes of death in the necropsies compared to SD-fed
animals (Supplementary Tables S1, S2 and S3).
Adult male C57BL/6 mice (from week 72 to 90) treated with 0.1% metformin were lighter
than control animals (Fig. 1c). Mice on metformin tended to preserve body weight with
advancing age, which has been associated with increased survival in rodent and human
studies31,32. By 124 weeks of age, the average weight of metformin-treated mice was higher
than SD-fed mice, although these observations were not found in B6C3F1 mice, probably
because food intake in this strain was controlled (Supplementary Fig. S1)33. Determinations
of body composition during the lifetime of the animals revealed no significant differences in
the percentage of fat mass and lean body mass or in the lean-to-fat ratio (Supplementary
Table S4). Although C57BL6/ mice fed with metformin were lighter, this group consumed
more calories than their SD counterparts, indicating a shift in energy metabolism (Fig. 1d).
The energy content of the feces was identical in both groups, suggesting that metformin did
not alter intestinal absorption of nutrients (Supplementary Fig. S1). However, the beneficial
effects of metformin might be explained, at least in part, by changes in the gut microbiota34,
a process that has not been addressed in our study. Nevertheless, the effect of metformin on
food consumption provides evidence against the possibility that metformin acts in a trivial
fashion by leading to caloric restriction attributable to lack of palatability of metformin-
supplemented chow.
We next examined whether the increase in calorie intake was associated with higher energy
expenditure. Indirect calorimetry revealed that metformin-treated animals showed higher
heat production during the dark phase, when mice are normally more active (Fig. 1e). In
accordance with previous reports demonstrating that metformin increases the use of lipids as
a source of energy35, the respiratory exchange ratio was decreased during both the light and
dark phases and liver glyceride content was reduced in metformin-treated mice, indicating
the preference for fat utilization (Fig. 1f and Supplementary Fig. S1). Consistent with this
Martin-Montalvo et al. Page 3
Nat Commun. Author manuscript; available in PMC 2014 January 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
hypothesis, β-oxidation of fatty acids was found to be increased while lipid synthesis was
decreased in primary hepatocytes and MEFs treated with metformin (Supplementary Fig.
S1). Interestingly, total levels of oxygen consumption and carbon dioxide production were
not modified significantly by metformin in mice (Supplementary Fig. S1). Moreover, there
was no difference in spontaneous locomotion activity, suggesting that metformin shifts
energy homeostasis of mice rather than their behavior (Supplementary Fig. S1).
While the effect of metformin on longevity was obvious, it was important to determine
whether the healthspan of the animals was preserved. We used several approaches to
ascertain physical health of the animals. Rotarod, treadmill and open-field tests indicated
that metformin improved the general fitness of laboratory mice (Fig. 1g, h and i). C57BL/6
mice are known to develop cataracts as they age32. Metformin supplementation led to
significant reduction in lens opacity of 105-week-old mice (Fig. 1j), consistent with an
overall improvement in healthspan.
As mentioned earlier, metformin is widely prescribed to improve insulin sensitivity. Mice
treated with 0.1% metformin showed lower glycated hemoglobin (Hb1Ac) levels 66 weeks
after the treatment was initiated (Table 1). Metformin-fed mice and mice on SD displayed
comparable glucose homeostasis when measured by oral glucose tolerance test (OGTT) and
insulin tolerance test (ITT) at 81 and 93 weeks of age, respectively (Fig. 1k–n). At 100
weeks of age, metformin-treated mice showed improvements in serum metabolite levels that
are associated with diabetes compared to their control counterparts, with a reduction in
insulin levels, total cholesterol, low density lipoproteins (LDL) and the homeostatic model
assessment index-Insulin Resistance (HOMA-IR) (Table 1). Taken together, these results
strongly suggest that metformin prevents the onset of metabolic syndrome.
Metformin mimics calorie restriction transcriptome
We have previously associated the induction of similar transcriptome to animals under CR
in liver tissue, even in a 8-week treatment15. To test whether metformin shifts the
physiology of ad lib-fed mice towards that of animals on CR after 30 weeks of treatment, we
performed a genome-wide microarray analysis on liver and muscle tissues of three groups of
mice ad lib-fed with SD, 0.1% metformin or CR.
Principal component analysis (PCA) demonstrated a clear effect of metformin treatment,
with the global gene expression profile shifting toward the changes induced by CR (Fig. 2a).
According to a previous report, further analysis of the transcript profile revealed that the
majority of the genes whose expression was modified by CR and 0.1% metformin were
shifted in the same direction in liver and muscle (Fig 2b)15. Of these, expression of the
cytokine-inducible SH2-containing protein (CISH) gene, which belongs to the cytokine-
induced STAT inhibitor family27, was one of the most highly induced genes found in the
liver and muscle of metformin- and CR-treated mice (Supplementary Table S5). Under the
metformin and CR regimen, the expression of serum amyloid protein genes (Saa1 and Saa2)
was markedly decreased in the liver, suggesting the suppression of inflammatory
responses36.
We used parametric analysis of gene-set enrichment (PAGE) analysis to further highlight
functional pathways modified in response to 0.1% metformin and CR. Both interventions
led to a significant overlap in the number of up- and down-regulated gene sets present in the
liver (84.7%) and muscle (85.6%), supporting that metformin closely mimics the CR
transcriptome (Fig. 2c)15. The liver has a central role in the maintenance of glucose
homeostasis and has been proposed as one of the main targets of metformin37. In the livers
of metformin-treated mice, PAGE analysis showed a significant alteration in 220 gene sets
(Supplementary Table S6), many of these were related to mitochondrial function, glycolysis,
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lipid biosynthesis, and stress response (Fig. 2d). In accordance with microarray data,
quantitative PCR indicated the increase in the mRNA levels of several genes encoding
transcriptional regulators and enzymes involved in mitochondrial energetics, glycolysis, and
fatty acid metabolism (Supplementary Fig. S2). Moreover, there was a significant down-
regulation of gene sets related to autophagy, apoptosis and ubiquitin cycle in the liver of
metformin-fed mice. Several stress response pathways were induced by metformin as shown
by Ingenuity Pathway Analysis (Supplementary Fig. S3). Nrf2 is a transcription factor that
regulates the expression of multiple antioxidant genes and is also required for the beneficial
effects of metformin in Caenorhabditis elegans10. Here, metformin treatment also induced
Nrf2 target gene activation. The overall interpretation of these results is that metformin
exerts CR-like genomic and metabolic responses by inducing longevity-associated pathways
in laboratory mice.
Preservation of mitochondrial function by metformin
It has been proposed that mild inhibition of the mitochondrial ETC complex I activity by
metformin21,22 reduces ATP production and contributes to increase the AMP/ATP ratio,
which, in turn, results in AMPK activation. AMPK plays an important role in the regulation
of energy metabolism38. In cultured mouse embryonic fibroblasts (MEFs) and in livers of
treated mice, metformin increased the relative levels of phosphoactive AMPK (Thr172) by
27% (p< 0.05, t-test two tailed), which led to increased phosphorylation at Ser-79 of its
direct target, acetyl-CoA carboxylase (ACC) by 169% (p<0.01, t-test two tailed) (Fig. 3a, b,
Supplementary Fig. S4, Supplementary Table S7 and Supplementary Table S8 for entire
western blot images and densitometric analyses). The ATP content in the liver of
metformin-treated mice was unaffected, which may stem from increased hepatic glycolysis
(Supplementary Fig. S5). In parallel, we examined mitochondrial performance in cultured
MEFs in response to metformin (Fig. 3c) and found a decrease in oxygen consumption rate,
in agreement with earlier reports39. Oxygen consumption was also decreased following the
addition of the mitochondrial uncoupler, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), which indicates that metformin altered
maximal oxygen consumption in MEFs. Cell culture media showed a reduction in pH on
exposure of cells to metformin (Supplementary Fig. S5), which is consistent with reports
showing increased lactic acid production due to an increase in glycolysis and studies that
associate the risk of lactic acidosis to metformin administration to diabetic patients40.
Furthermore, metformin induced the expression of cytosolic lactate dehydrogenase, the
enzyme responsible for lactic acid production, both in MEFs and in the liver of treated
animals (Supplementary Fig. S5).
Our microarray and quantitative PCR analyses showed increased expression of several
mitochondrial genes in the livers of metformin-treated mice. However, metformin lowered
oxygen consumption in MEFs, suggesting that these alterations in mitochondrial
bioenergetic function may occur in cell cultures. The administration of this anti-diabetic
drug did not alter several markers of mitochondrial content in both MEFs and the liver of
treated mice (Fig. 3d, e and f), while causing only moderate increase, if any, in the
expression of several subunits in the ETC complexes (Fig. 3g and h). Among key enzymes
of the tricarboxylic acid cycle and ETC that were assayed, complex I activity was
significantly lower in metformin-treated MEFs (Fig. 3i). In contrast, mice treated with
metformin had a remarkable increase in hepatic complex I activity (Fig. 3j). The activity for
complexes III and IV was significantly reduced by metformin in MEFs, but remained
unchanged in liver lysates of metformin-treated mice. The differential effects of metformin
in vitro and in vivo may be due to the hepatocytes adapting to long-term inhibition of
complex I activity. Interestingly, and in agreement with our findings, preservation of
mitochondrial complex I activity, at least in muscle, has been recently reported after long-
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term metformin treatment in humans41. Furthermore, the inhibition of mitochondrial
respiration by metformin is reported to be concentration-dependent, with no effect at
concentrations lower than 1 mM42. Serum level of metformin was 0.45 ± 0.09 mM (Mean ±
SEM) in 0.1% metformin-treated mice, which is considerably higher than seen in the serum
of diabetic patients treated with metformin43, but lower than those used in most in vitro
models that demonstrate inhibition of mitochondrial respiration by this compound21,22,42.
The degree of inhibition of oxidative phosphorylation as a function of metformin serum
levels cannot be quantitated because of the fact that active uptake of metformin occurs via
transporters on the cell surface and, possibly, mitochondria.
Metformin inhibits chronic inflammation—The activation of the SKN-1/Nrf2-
dependent antioxidant response is required for the beneficial effects of metformin in
Caenorhabditis elegans10. There was a trend towards reduction in superoxide production in
mitochondrial complexes in the livers of metformin-treated mice (p=0.09, t-test two tailed)
(Supplementary Fig. S6). When divided by the total activity of mitochondrial complexes I–
II to III, the proportion of superoxide leakage was significantly decreased by metformin
(Fig. 4a), indicating greater efficiency of mitochondrial complexes in transferring electrons
to their expected acceptors in the ETC. Moreover, the marked reduction in the amount of
lysine-4-hydroxynonenal-modified proteins and 8-iso-PGF2α, a marker of lipid
peroxidation, was consistent with decreased oxidative stress damage in the liver of
metformin-treated mice (Fig. 4b and c). To investigate whether metformin activates the
Nrf2-dependent antioxidant response, HepG2 cells stably expressing a Nrf2-responsive
Antioxidant Response Element (ARE) luciferase reporter construct were treated with
increasing concentrations of metformin for 16 h (Fig. 4d). The increase in Nrf2/ARE
reporter activity occurred with an ED50 of ~1.5 mM metformin without reduction in cell
survival (Supplementary Fig. S6). The cellular reduction of the tetrazolium dye MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), an assay that measures
NADH-oxidase activity, was lower in metformin-treated cells, with an IC50 of ~ 3.3 mM
(Supplementary Fig. S6). Lastly, in the livers of treated mice, 0.1% metformin contributed
to an increase in the level of antioxidant and stress response proteins, including SOD2,
TrxR1, NQO1 and NQO2 (Fig. 4e), further contributing to the reduction in hepatic oxidative
stress damage.
The development of chronic inflammation is one of the hallmarks of oxidative damage
accumulation. Inflammatory processes contribute to liver dysfunction in aging and are
known to be suppressed by CR44. In this context, increases in the relative levels of
phosphoactive forms of NF-κB and JNK have been shown to contribute to pro-inflammatory
signaling45,46. Interestingly, metformin reduces the production of inflammatory markers in
human liver cells36. In the livers of metformin-treated mice, a decline in pNF-κB by 64%
(p< 0.01, t-test two tailed) and pJNK by 79% (p< 0.01, t-test two tailed) levels was observed
(Fig. 4f) together with attenuated expression of NF-κB gene (Fig. 4f). An additional gene
expression signature associated with metformin treatment was the increased expression of
several anti-inflammatory genes (Fig 4g). These results are in agreement with the fact that
metformin reduces the number of activated macrophages, although we could not detect
significant differences in the number of infiltrated macrophages in the liver of the mice
(Supplementary Fig. S6). Further research will be required to address this fact. In summary,
the ability of metformin to reduce oxidative stress and inflammation suggests that this could
partly be the reason why this drug confers health and lifespan benefits in laboratory mice.
Discussion
Our model reveals a level of chronic metformin exposure that lengthens lifespan and also
attenuates the deleterious effects of aging in male mice. The effects of metformin resembled
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to some extent the effects of caloric restriction, even though food intake was increased.
While it is clear that in short-term in vitro models, metformin partially inhibits oxidative
phosphorylation, we find no evidence for this with long-term exposure in vivo, suggesting
that adaptation to metformin occurs, and is associated with benefits, including reduced
oxidative stress and increased antioxidant defenses, leading to lower oxidative damage
accumulation and inhibition of chronic inflammation. The dose associated with these
beneficial effects was well tolerated in mice, but lead to serum levels an order of magnitude
higher than those conventionally used in treatment of diabetes in human patients. Thus,
while the pleotropic effects of metformin in vivo presents challenges in the identification of
the specific mechanisms that are critical for the observed improvements on health and aging,
pharmacokinetic issues must be addressed before results from our model can be extrapolated
to other species. Further studies are required to determine the effects of chronic exposure
levels to biguanides in health and aging in humans.
Methods Summary
Animal models and diets
Animal procedures, housing and diets were in accordance with the guidelines issued by the
Intramural Research Program of the National Institutes of Health protocol number
352TGB2013. Male C57BL/6 mice at either 6 months of age (for 0.1% metformin and CR)
or 11 months of age (for 1% metformin dose) were purchased from the National Institute on
Aging Aged Rodent Colony from Charles Rivers. The C57BL/6 mice were maintained on a
standard purified mouse diet (AIN-93G) until they reached one year of age when the
treatments started. The CR animals were subjected to a lifelong restriction on AIN-93G diet,
starting at 27 weeks of age, with a daily food allotment of 60% of that eaten by the ad lib
animals. Besides CR animals, the C57BL/6 groups in this study were fed the standard
AIN-93G diet (SD) or AIN-93G plus 0.1% metformin or 1% metformin ad lib for the
remainder of their lives. Pure metformin was obtained from Farmhispania (Farmhispania
S.A. Barcelona, Spain) and mixed to homogeneity during manufacturing of the diets (Dyets
Inc., Bethlehem, PA). For B6C3F1 mice longevity study, male mice (Harlan Breeders;
Indianapolis) were randomly assigned to treatment groups at 12 months of age. In the
control group, mice were shifted from ad lib chow feeding (Diet # 5001, Purina Mills,
Richmond, IN) to daily feeding with 13.3 kcal/day/mouse of control diet (AIN-93M, Diet
No. F05312; BioServ, Frenchtown, NJ). For the metformin B6C3F1 group, mice were
shifted to daily feeding with an identical quantity of control AIN-93M diet supplemented
with metformin (Caraco Pharmaceutical Laboratories, Detroit, MI) at 100 mg/kg diet (0.1%
w/w) (~10.6 mg/kg bw/day). All mice were fed daily and, with rare exceptions, all food was
eaten each day. Metformin was mixed with powdered diet and cold-pressed into 1-g pellets
by BioServ (BioServ, Frenchtown, NJ). The chow was produced every 3 months during the
length of the study, never was permitted to exceed 50 °C and was kept away from light
whenever possible to ensure the stability of metformin (the light/dark cycle in the mouse
facility was not altered). Stock metformin and all chow were stored in the dark at 4 °C. The
mice were on a light:dark 12:12-h schedule and maintained between 20–22 °C according to
animal protocols and NIH guidelines. Food intake and body weight were measured on a
biweekly or bimonthly basis for the duration of the study. Survival curves were plotted using
the Kaplan-Meier method, which includes all available animals at each time point. The
criteria for euthanasia was based on an independent assessment by a veterinarian, according
to AAALAC guidelines and only cases, where the condition of the animal was considered
incompatible with continued survival, are represented in the curves. Every animal found
dead or euthanized was necropsied for pathology score. The C57BL/6 0.1% metformin
group started with 64 mice and the corresponding 83 corresponding SD control mice. CR
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group; 76 mice. The C57BL/6J 1% metformin group; 90 mice. SD matched group; 88 mice.
The B6C3F1 0.1% metformin group; 36 mice. SD matched group; 297 mice.
Faecal analysis
Total energy in faeces was determined in 0.6±0.04 g of fecal samples in a 1281 Oxygen
Bomb Calorimeter (Parr Instrument, Moline, IL) according to the manufacturer’s protocol.
(n = 3–5 per group; age = 66 weeks; diet = 12 weeks).
Metabolic Clamps
Mouse metabolic rate was assessed by indirect calorimetry in open-circuit oxymax chambers
using the Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments,
Columbus, OH). Mice were housed singly with water and food available ad lib, except for
CR group, and maintained at 20–22 °C under a 12:12-h light-dark cycle (light period 0600–
1800). All mice were acclimatized to monitoring cages for 3–6 h prior to recording. Sample
air was passed through an oxygen sensor for determination of oxygen content. Oxygen
consumption was determined by measuring oxygen concentration in air entering the
chamber compared with air leaving the chamber. The sensor was calibrated against a
standard gas mix containing defined quantities of oxygen, carbon dioxide and nitrogen.
Constant airflow (0.6 L/min) was drawn through the chamber and monitored by a mass-
sensitive flow meter. The concentrations of oxygen and carbon dioxide were monitored at
the inlet and outlet of the sealed chambers to calculate oxygen consumption. Measurement
in each chamber was recorded for 30 s at 30-min intervals for a total of 60 h. The second
dark:light cycle is represented in the plots. Movement (both horizontal and vertical) was also
monitored. The system has beams 0.5 inches apart on the horizontal plane, providing a high-
resolution grid covering the XY-planes and the software provides counts of beam breaks by
the mouse in 30-s epochs (n = 9 per group; age = 71 weeks; diet = 17 weeks).
Physical performance tests
Results from rotarod, treadmill and open-field are presented as follows: Time to fall from an
accelerating rotarod (4–40 r.p.m. over 5 min); total distance ran in the treadmill test until
exhaustion; and the speed of the animals in the open-field. Rotarod: Mice were given a
habituation trial on day 1 where they were placed on the rotarod at a constant speed (4 rpm)
and had to remain on the rotarod for 1 min. Results shown are the average of 3 trials per
mouse, measuring time to fall from an accelerating rotarod (4–40 rpm over 5 min). The
maximum trial length was 5 min, and there was a 30-min rest period between each trial (n =
16 per group; age = 95 weeks; diet = 41 weeks). For the treadmill test, mice were required to
exercise on the treadmill until exhaustion. The treadmill was horizontal (0° incline) and
mice ran in groups of 6. Subjects were habituated at a constant speed of 4 m.min−1 for 5
min. The following day each mouse was given a trial starting at 7 m.min−1 for 0–3 min, 12
m.min−1 for 3–7 min, 15 m.min−1 for 7–25 min, and 19 m.min−1 for 25 min (n = 9 per
group; age = 73 weeks; diet = 19 weeks). For open-field determinations, mice were placed
on the field and movement was recorded for 300 s using Field 2020 tracking software from
HVS Image. Results were averaged for movement speed (n = 15–16 per group; age = 95
weeks; diet = 41 weeks).
Insulin, OGTT and ITT
To determine glucose and insulin levels, blood samples were collected by venipuncture and
analyzed as described in Supplementary Information7.
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Serum markers and hormones
Serum metabolites were quantified using a COBAS Integra 400 instrument according to the
manufacturer’s instructions (Roche, Indianapolis, IN). HbA1c levels were determined
according to the manufacturer’s protocol using the mouse HbA1c kit (Crystal Chem,
Downers Grove, IL).
Microarray analysis
RNA from tissues was isolated using the RNeasy kit (Qiagen, Valencia, CA) and then
hybridized to BD-202-0202 Illumina Beadchips. Raw data were subjected to Z-
normalization, as described elsewhere47,48. Principal component analysis, performed on the
normalized Z-scores of all of the detectable probes in the samples, was performed by using
the DIANE 6.0 software (http://www.grc.nia.nih.gov/branches/rrb/dna/diane_software.pdf).
Significant genes were selected by the z-test < 0.05, false discovery rate < 0.30, as well as z-
ratio > 1.5 in both directions and ANOVA p value < 0.05. Parametric analysis of gene set
enrichment (PAGE) was analyzed as previously described49. Gene regulatory network and
canonic pathway analysis was performed by using Ingenuity Pathway Analysis (IPA).
Oxygen consumption
Oxygen consumption in MEFs was measured using the Seahorse 24XF instrument (Seahorse
Biosciences, North Billerica, MA). In brief, cells were seeded into Seahorse tissue culture
plates and treated without or with 1 mM metformin for 16 h. Then, the medium was changed
and the assay was run. A detailed explanation of the protocol is included in Supplemental
Information.
Nrf2/ARE pathway activity
Nrf2 induction was determined according to the manufacturer’s protocols (Invitrogen, La
Jolla, CA). A detailed explanation of the protocols is described in Supplementary
Information.
Mitochondrial mass determination
2 × 106 MEFs were seeded in a 100 mm culture dish. After 24 h, cells were washed once in
PBS, trypsinized, and then resuspended in phenol red-free DMEM supplemented with 10%
FBS containing either 50 nM MitoTracker Green FM (Invitrogen) or 20 nM
Tetramethylrhodamine methyl ester (TMRM) (Invitrogen). Cells stained with TMRM were
incubated for 15 min at 37 °C while 30-min incubations were used for MitoTracker Green
FM. Fluorescence was measured by a flow cytometer (C6 Flow Cytometer, Accuri, MI).
Superoxide generation
Superoxide production was determined in liver samples by the reduction of acetylated
cytochrome c50 according to a method described previously for succinate:NADH-
cytochrome c reductase with minor modifications51.
Lipid peroxidation
Lipid peroxidation was determined by quantifing the levels of 8-iso-Prostaglandin F2α
according to the manufacturer’s protocol using the 8-iso-PGF2α ELISA kit (Enzo Life
Sciences, Farmington, NY).
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Body Composition
Several times during the length of the study, the amounts of body fluid, fat, and lean body
mass were determined in whole live mice. The assessment was acquired by nuclear
magnetic resonance (NMR) using the Minispec LF90 (Bruker Optics, Billerica, MA).
Statistical analysis
Unless otherwise stated, Student’s t-test two tailed assuming unequal variances was used.
Analyses were performed using Excel 2010 (Microsoft Corp., Redmond, WA). For
longevity studies Gehan-Breslow statistical test was used and analyses were performed
using sigmastat 3.5 (Systat Software Inc., San Jose, CA). Microarray data is accessible in
GEO database under accession code GSE40936. In all experiments results are represented as
the mean ± SEM. In all cases p values ≤ 0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Metformin increases survival and improves physical performance
(a, b) Kaplan–Meier survival curve for mice treated either with 0.1% or 1% metformin. n =
64 for metformin 0.1% group and n = 83 for their untreated counterparts; n = 90 for
metformin 1% group and n = 88 for their untreated counterparts. The arrows at 54 weeks
indicate the age at which metformin treatment was initiated. (c) Body weights. (d) Food
consumption. (e, f) In vivo metabolic response to 0.1% metformin treatment. n = 9 per
group. (e) Energy expenditure. (f) Respiratory exchange ratio. (g) Time to fall from an
accelerating rotarod. n = 16 per group. (h) Distance ran on treadmill performance. n = 9 per
group. (i) Average speed of animals in the open-field test. n = 15–16 per group. (j)
Metformin treatment delayed the onset of age-related cataracts. n = 93–124 eyes per group.
(k) Plasma levels of glucose after oral glucose load (OGTT). n = 8 per group. (l) Area under
OGTT curve. (m) Plasma levels of glucose after intraperitoneal insulin injection (ITT). n = 9
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per group. (n) Area under ITT curve. Metformin, Met. Unless otherwise stated n = all live
animals in the study. Data are represented as the mean ± SEM. * p < 0.05 compared to
standard diet (SD)-fed mice (t-test two tailed).
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Figure 2. Metformin shifts expression patterns of mice towards those on calorie restriction
(a) Principal component analysis (PCA) was performed on differentially expressed genes
from the liver and muscle tissue of mice maintained on SD and 0.1% metformin. Each data
point corresponds to the PCA analysis of each subject. (b) Gene expression profile
comparing genes significantly up- (red) and down-regulated (blue) by either calorie
restriction (CR) or metformin compared to SD mice (z-ratio). The percentage of significant
gene expression changes shifted in the same direction in CR and metformin treatments
compared to SD mice is presented in brackets. (c) Comparison of gene sets significantly
altered by CR and metformin treatment compared to SD expression (z-score); up- (red) and
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down-regulated (blue) gene sets. The percentage of significant gene sets changes shifted in
the same direction in CR and metformin treatments compared to SD mice is presented in
brackets. (d) Effect of metformin on mitochondria (Mito), glycolysis, lipid metabolism
(Lipid Met) and stress response (Stress Resp) related gene sets. The list of all the
significantly modified gene sets can be found in Supplementary table S6. Metformin, Met;
Calorie restriction, CR.
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Figure 3. Metformin activates AMPK without altering in vivo electron transport chain activities
(a) Activation of AMPK by metformin in MEFs. AMPK and acetyl-coA carboxylase (ACC)
phosphorylation by metformin. n = 3 per group. (b) Activation of AMPK and ACC
phosphorylation in the liver of 0.1% metformin-treated mice. n = 4–6 per group. (c) Oxygen
consumption in MEFs treated with 1 mM metformin. n = 3 per group. (d, e), Mitochondrial
content in MEFs treated with metformin was determined by tetramethyl rhodamine methyl
ester (TMRM) (d) and MitoTracker green (e) staining, M.F.I., mean fluorescence intensity.
n = 3 per group. (f) Mitochondrial DNA content analyzed by quantitative PCR in the liver. n
= 5–8 per group. (g) Mitochondrial protein levels in MEFs treated with metformin. n = 3 per
Martin-Montalvo et al. Page 17
Nat Commun. Author manuscript; available in PMC 2014 January 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
group. (h) Mitochondrial protein levels in the liver from 0.1% metformin-treated mice. n =
4–6 per group. (i, j) Effect of metformin on mitochondrial enzymatic activities. (i) MEFs
treated with 1 mM metformin (n = 3 per group) and (j) Liver lysates from 0.1% metformin-
treated mice (n = 5–6 per group). Metformin, Met: Calorie restriction, CR; Ut, untreated.
Data are represented as the mean ± SEM. * p < 0.05 versus untreated controls or standard
diet (SD)-fed mice (t-test two tailed).
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Figure 4. Metformin enhances antioxidant defenses and inhibits inflammation
(a) Rate of electrons derived to superoxide generation in mitochondrial complexes I and II
to III in the liver of 0.1% metformin-treated mice. n = 5–6 per group. (b) Oxidative damage
in proteins determined by lysine-4-hydroxinonenal levels in the liver of 0.1% metformin-
treated mice. (n = 4–6 per group) (c) Oxidative damage in lipids determined by 8-iso-PGF2α
levels in the liver of 0.1% metformin-treated mice. (n = 4–6 per group) (d) Nrf2-ARE assay
determining Nrf2-ARE-dependent expression in metformin-treated HepG2 cells. tBHQ was
added as positive control for NRF2-ARE induction. (n = 3 per group) (e) Antioxidant and
stress response protein levels in the liver of 0.1% metformin-treated mice. (n = 4–6 per
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group) (f) Activation of pro-inflammatory signaling pathways in the liver of 0.1%
metformin-treated mice. (n = 4–6 per group) (g) Expression of multiple inflammatory-
related genes in the liver of 0.1% metformin-treated mice. (n = 5 per group) Metformin,
Met; Calorie restriction, CR. Data are represented as the mean ± SEM. * p < 0.05 versus
standard diet (SD)-fed mice (t-test two tailed).
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Table 1
Effects of 0.1% metformin treatment on various serum biomarkers
Parameter Standard Diet (SD) 0.1% Metformin CR
Ala aminotransferase (U/L) 90 ± 58 64 ± 29 50 ± 15
Cholesterol (mg/dl) 221 ± 30 143 ± 33* 101 ± 8*
Creatinine (mg/dl) 0.11 ± 0.01 0.13 ± 0.01* 0.27 ± 0.25
Lactate 573 ± 82 623 ± 165 443 ± 109
Dehydrogenase (u/L)
Low Density 40 ± 10 17 ± 10* 16 ± 5*
Lipoprotein (mg/dl)
Triglycerides (mg/dl) 106 ± 28 129 ± 50 45 ± 7*
Total protein (g/dl) 6.00 ± 0.39 6.04 ± 0.32 5.28 ± 0.04*
Glucose–fed (mM) 10.94 ± 0.35 11.33 ± 0.76 ND
Glucose–fasted (mM) 8.23 ± 0.65 8.80 ± 0.43 4.10 ± 0.42*
Insulin (pM) 428.08 ± 34.26 297.64 ± 29.72* 46.75 ± 16.76*
% HbA1c 6.33 ± 0.47 5.81 ± 0.57* ND
HOMA-IR index 8.01 ± 0.57 5.87 ± 0.47* 0.84 ± 0.30*
Insulin and glucose levels were determined at 100 weeks of age and HbA1c was determined at 66 weeks of age. All other determinations were
assayed at 74 weeks of age. Values shown are mean ± Standard Deviation; n = 4–16 samples per group.
*p < 0.05 versus standard diet (SD) (t-test two tailed);
CR, calorie restricted; ND, not determined.
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